Apollo Hospitals

NSE: APOLLOHOSP · Healthcare

₹7,468.50

▼ -0.42%

SELL

Illustrative research · not investment advice Demo price · quote unavailable · Fundamentals and research: sample dataset (30 Oct 2026)

Price chart

Illustrative price history · not actual market candles

A. Company overview

Largest private hospital chain in India.

Market cap

₹1,96,18,728 Cr

Industry / Sector

Healthcare

Segments

Website

Visit ↗

HospitalsPharmacyDigital Health

B. Fundamental analysis (illustrative)

Revenue growth

+7.75%

Net profit growth

+4.48%

Operating margin

11.01%

EBITDA margin

13.55%

ROE

30.17%

ROCE

34.7%

Debt / Equity

EPS

₹170.86

Operating cash flow

₹64,642 Cr

Working capital

₹45,466 Cr

5-year revenue & profit (₹ Cr)

C. Financial statements (illustrative)

₹ Cr	FY22	FY23	FY24	FY25	FY26
Revenue	4,05,134	4,38,739	4,91,561	5,27,257	5,68,324
EBITDA	61,181	60,124	57,836	71,956	76,985
Net profit	38,238	37,578	36,148	44,972	48,116
EPS (₹)	119.6	133.27	146.94	160.61	174.28

D. Valuation analysis

P/E

43.71

P/B

6.96

EV/EBITDA

19.77

Price/Sales

1.3

EPS

₹170.86

Dividend yield

1.76%

Peer comparison — Healthcare

No sector peers in the demo universe.

E. Technical analysis

RSI (14)

66.44

MACD

-3.28

Support

₹7,095.08

Resistance

₹7,916.61

Volume

60,11,475

Illustrative technical charts · not actual market history

Candlestick (last 50 sessions)

Price with 50-DMA & 200-DMA, volume

Fibonacci retracement levels

23.6% · ₹7356.68

38.2% · ₹7219.85

50.0% · ₹7109.27

61.8% · ₹6998.69

F. Shareholding pattern

Promoter61.55%

FII10.65%

DII9.32%

of which Mutual Funds5.8%

Public18.48%

G. SWOT analysis

Strengths

Established position in Healthcare
ROE of 30.17% in demo data

Weaknesses

Limited pricing power in some segments
Cyclical exposure

Opportunities

Domestic demand growth
Expansion in Hospitals

Threats

Regulatory changes
Competitive intensity

Illustrative template points for demonstration.

H. Research conclusion

Financial strength

Moderate leverage to monitor

Business quality

High capital efficiency

Valuation

Premium valuation

Growth

Sales growth of 7.75%

Risk assessment

Medium risk

Overall

Illustrative SELL opinion · target ₹6,698.68 · stop loss ₹6,830.94

I. Corporate actions

Dividend history (₹/share)

Year	Dividend
FY22	105.15
FY23	113.04
FY24	120.93
FY25	128.81
FY26	136.7

Bonus, splits & announcements

Bonus history: none in demo dataset
Stock split history: none in demo dataset
Board meeting for quarterly results — demo announcement